Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

08.02.16	Biogen Joins Pioneering Target Validation Collaboration (Businesswire)
27.01.16	Biogen Reveals 2016 Financial Guidance - Quick Facts (RTTNews)
27.01.16	Biogen Inc. Reveals 3% Gain In Q4 Earnings (RTTNews)
17.01.16	BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union (Businesswire)
05.01.16	Jacobs Wins Contract With Biogen - Quick Facts (RTTNews)
08.12.15	Biogen Says Data From Eloctate & Alprolix Help Control Of Bleeding In Hemophilia (RTTNews)
08.12.15	New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B (Businesswire)
24.11.15	Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A (Businesswire)
20.11.15	Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP (Businesswire)
21.10.15	Biogen Q3 Profit Tops Estimates; To Axe 11% Of Its Workforce (RTTNews)
21.10.15	Biogen Inc. Reveals 16% Advance In Q3 Bottom Line (RTTNews)
21.10.15	Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS (Businesswire)
12.10.15	Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World (Businesswire)
09.10.15	Biogen Announces Departure of Tony Kingsley (Businesswire)
08.10.15	Biogen Reports Positive Results From ZINBRYTA Phase 3 DECIDE Study (RTTNews)
07.10.15	Biogen: New Data Show Sustained Effects Of TECFIDERA - Quick Facts (RTTNews)
07.10.15	New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients (Businesswire)
01.10.15	Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment (Businesswire)
25.09.15	Biogen, Sobi Get Positive CHMP Opinion For ELOCTA For Treatment Of Hemophilia A (RTTNews)
25.09.15	Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A (Businesswire)
11.09.15	Biogen Named the Global Biotechnology Industry Leader on Dow Jones Sustainability World Index for Second Consecutive Year (Businesswire)
11.09.15	Biogen Prices Four Series Of Senior Unsecured Notes - Quick Facts (RTTNews)
09.09.15	Biogen Licenses Mitsubishi Tanabe's Phase 2 Molecule MT-1303 - Quick Facts (RTTNews)
08.09.15	Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer’s Disease (Businesswire)
18.08.15	Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS (Businesswire)
10.08.15	Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia (Businesswire)
24.07.15	Biogen Q1 Adj. Profit Tops View, But Revenues Miss; Trims 2015 Outlook (RTTNews)
24.07.15	Pre-market Movers For July 24 (CI, ANTM, AMZN, AAL, BIIB, XRX, TRUE, LEA) (RTTNews)
24.07.15	Biogen Q2 Adj. Profit Tops View - Quick Facts (RTTNews)
24.07.15	EARNINGS SUMMARY: Details of Biogen Inc. Q2 Earnings Report (RTTNews)
22.07.15	Pre-market Movers For July 22 (BA, WHR, THOR, AAPL, MSFT, YHOO, BIIB) (RTTNews)
22.07.15	Biogen Reports New Data From Phase 1B Study Of Aducanumab In Alzheimer's Disease (RTTNews)
22.07.15	Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015 (Businesswire)
10.07.15	Douglas Williams to Leave Biogen for Biotechnology Start-Up (Businesswire)
03.07.15	VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets A Date With FDA (RTTNews)
02.07.15	Biogen Obtains Worldwide Commercialization Rights For XLRS And XLRP Programs (RTTNews)
02.07.15	Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology (Businesswire)
26.06.15	Biogen Says European Medicines Agency Validates MAA For ALPROLIX - Quick Facts (RTTNews)
26.06.15	Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX® (rFIXFc) Marketing Authorization Application (Businesswire)
10.06.15	Biogen, Samsung Bioepis Report Positive Results For 3 Anti-TNF Candidates (RTTNews)
10.06.15	Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress (Businesswire)
13.05.15	Biogen Names Matt Griffiths as Chief Information Officer (Businesswire)
08.05.15	After-market Movers For May 7 (CBS, BIIB, DATA, NVDA, YELP, MNST, SFM, FLDM) (RTTNews)
07.05.15	Biogen Authorizes Stock Buyback Of $5 Bln (RTTNews)
07.05.15	Biogen Announces $5 Billion Share Repurchase Program (Businesswire)
29.04.15	FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS (Businesswire)
24.04.15	Biogen Q1 Results Miss Estimates (RTTNews)
24.04.15	Pre-market Movers For April 24 (AZN, BIIB, XRX, MSFT, AMZN, GOOGL, SBUX, CMCSA) (RTTNews)
24.04.15	Biogen Q1 Profit Rises - Quick Facts (RTTNews)
21.04.15	Biogen Records Consistent Long Term Safety/Efficacy Data For Plegridy (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende
19.11.24		Schwacher Handel: SDAX fällt nachmittags
19.11.24		Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste
19.11.24		Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer
19.11.24		Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende

19.11.24

Schwacher Handel: SDAX fällt nachmittags

19.11.24

Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste

19.11.24

Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer

19.11.24

Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Biogen Inc

Aktien Top/Flop

Biogen Peer Group Nachrichten

Meistgelesene Nachrichten